PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33396223-5 2020 RESULTS: LPS/GalN injection generate distinct molecular processes, which includes increased production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), thus causing apoptosis as evident by increased caspase-3 activity. Galactosamine 13-17 interleukin 6 Mus musculus 150-163 33760163-10 2021 In conclusion, the findings of the present study suggested that in a D-GalN/LPS-induced ALF model, TNF-alpha and IL-6 signaling may increase MLCK and ROCK expression levels, further mediate phosphorylation of MLC, which may result in tight junction dysregulation and intestinal barrier dysfunction. Galactosamine 69-75 interleukin 6 Mus musculus 113-117 33396223-5 2020 RESULTS: LPS/GalN injection generate distinct molecular processes, which includes increased production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), thus causing apoptosis as evident by increased caspase-3 activity. Galactosamine 13-17 interleukin 6 Mus musculus 165-169 30597306-5 2019 Moreover, AGD significantly inhibited LPS/GalN-induced inflammatory responses in mice with ALI by reducing not only the secretion of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 but also the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Galactosamine 42-46 interleukin 6 Mus musculus 197-201 28822324-0 2017 Preventive effects of interleukin-6 in lipopolysaccharide/d-galactosamine induced acute liver injury via regulating inflammatory response in hepatic macrophages. Galactosamine 58-73 interleukin 6 Mus musculus 22-35 28822324-1 2017 Lipopolysaccharide/d-Galactosamine (LPS/d-Gal)-induced acute liver injury is characterized by significant inflammatory responses including TNF-alpha and interleukin-6 (IL-6) and is a widely applied experimental model for inflammation research. Galactosamine 19-34 interleukin 6 Mus musculus 153-166 28822324-1 2017 Lipopolysaccharide/d-Galactosamine (LPS/d-Gal)-induced acute liver injury is characterized by significant inflammatory responses including TNF-alpha and interleukin-6 (IL-6) and is a widely applied experimental model for inflammation research. Galactosamine 19-34 interleukin 6 Mus musculus 168-172 19642894-0 2009 Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamine-induced liver damage. Galactosamine 67-82 interleukin 6 Mus musculus 0-13 25382719-4 2014 GalN/LPS increased serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, while 1 attenuated TNF-alpha levels and further increased IL-6 levels. Galactosamine 0-4 interleukin 6 Mus musculus 69-82 25382719-4 2014 GalN/LPS increased serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, while 1 attenuated TNF-alpha levels and further increased IL-6 levels. Galactosamine 0-4 interleukin 6 Mus musculus 84-88 25382719-4 2014 GalN/LPS increased serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, while 1 attenuated TNF-alpha levels and further increased IL-6 levels. Galactosamine 0-4 interleukin 6 Mus musculus 156-160 25325613-4 2014 Treatment with GalN/LPS resulted in increased levels of serum alanine aminotransferase, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6, as well as increased mortality, all of which were attenuated by treatment with 1. Galactosamine 15-19 interleukin 6 Mus musculus 127-145 25325613-8 2014 Following GalN/LPS treatment, nuclear translocation of nuclear factor-kappaB and the levels of TNF-alpha and IL-6 mRNA expression increased, which were attenuated by 1. Galactosamine 10-14 interleukin 6 Mus musculus 109-113 19818826-9 2010 GalN/LPS increased the circulating levels of tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6) and IL-10. Galactosamine 0-4 interleukin 6 Mus musculus 80-93 19818826-9 2010 GalN/LPS increased the circulating levels of tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6) and IL-10. Galactosamine 0-4 interleukin 6 Mus musculus 95-99 19818826-11 2010 GalN/LPS treatment also increased the levels of TNF-alpha, IL-6 and IL-10 mRNA expression in liver tissue. Galactosamine 0-4 interleukin 6 Mus musculus 59-63 7890366-0 1995 Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice. Galactosamine 151-166 interleukin 6 Mus musculus 31-44 7522168-6 1994 Furthermore, IL-6(0/0) mice could be equally well desensitized (by IL-1) to TNF/GalN-induced lethality and tolerized to TNF-induced shock as IL-6+/+ mice. Galactosamine 80-84 interleukin 6 Mus musculus 13-17 1657127-8 1991 We conclude that the strongly enhanced sensitivity of GalN-treated mice towards mTNF-induced or LPS-induced lethality was not reflected in circulating TNF or IL-6 levels, and that dexamethasone and indomethacin both reduce circulating IL-6 concentrations in mice treated with TNF and LPS. Galactosamine 54-58 interleukin 6 Mus musculus 235-239 34490261-5 2021 Furthermore, Zdhhc11 knockout mice had a lower level of serum IL6 upon treatment with LPS and D-galactosamine or HSV-1 infection than control mice. Galactosamine 94-109 interleukin 6 Mus musculus 62-65 35485445-7 2022 Moreover, PEA treatment significantly reduced mortality and serum IL-6 levels in mice injected with CpG-ODN plus D-galactosamine. Galactosamine 113-128 interleukin 6 Mus musculus 66-70 17420605-6 2007 Moreover, CS and alpha-EG suppressed the GalN-induced production of interleukin 6 (IL-6) and liver DNA fragmentation. Galactosamine 41-45 interleukin 6 Mus musculus 68-81 17420605-6 2007 Moreover, CS and alpha-EG suppressed the GalN-induced production of interleukin 6 (IL-6) and liver DNA fragmentation. Galactosamine 41-45 interleukin 6 Mus musculus 83-87 17420605-7 2007 Together these results show that CS and its component, alpha-EG, suppressed GalN-induced liver injury by inhibiting IL-6 production. Galactosamine 76-80 interleukin 6 Mus musculus 116-120 16901963-5 2006 Administration of a low dose of LPS (100 or 10 ng/g) in association with d-galactosamine induced equivalent mortality rates, hepatotoxicity, and serum IL-6 in WT and APN KO mice. Galactosamine 73-88 interleukin 6 Mus musculus 151-155 14985352-8 2004 Finally, we show that d-galactosamine-sensitized IL-6-deficient mice were partially resistant to endotoxin-induced liver apoptosis and lethality. Galactosamine 22-37 interleukin 6 Mus musculus 49-53 8758269-4 1996 The serum total bilirubin (TBIL) and liver necrosis of mice increased more markedly by using of TNF alpha, IL-6 or IFN gamma separately with D-GAL (TBIL: 46.2 +/- 10.6 micromol/L, 44.6 +/- 12.9 micromol/L, 41.9 +/- 14.9 micromol/L), then by D-GAL alone (TBIL: 27 +/- 11 micromol/L) also the serum TBIL of mice and liver necrosis also increased after injection of IL-1, IL-6 with D-GAL and TNF alpha. Galactosamine 141-146 interleukin 6 Mus musculus 369-373 8454355-0 1993 Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Galactosamine 59-72 interleukin 6 Mus musculus 19-32